Trial Profile
A Phase 1 Study to Evaluate the Safety and Pharmacokinetic Profile of CBLB502 in Patients With Advanced Cancers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Jul 2022
Price :
$35
*
At a glance
- Drugs Entolimod (Primary) ; Entolimod (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 02 Jun 2015 Status changed from active, no longer recruiting to completed, based on results reported at the 2015 annual meeting of the American Society of Clinical Oncology (ASCO).
- 01 Jun 2015 Results published in the Cleveland BioLabs media release.